HeadwaterCompany strategiesBuild yours

AstraZeneca

$80 billion by 2030, May 2024 to 2030

Today AstraZeneca announces a new era of growth
Pascal Soriot, AstraZeneca’s CEO, at the Investor Day, May 2024

$80 billion by 2030

In 2023 AstraZeneca reached the $45 billion revenue goal it had set a decade earlier, and set the next: $80 billion by 2030, with sustained growth after it. To get there it plans to grow its existing oncology, biopharmaceuticals, and rare disease medicines, launch 20 new medicines by 2030, and invest in technologies for the decade after, while cutting its carbon emissions.

Grow today’s medicines

Oncology Total Revenue rose 15% to $14.1 billion in the first half of 2026, 46% of the total, and Rare Disease rose 11%.

Cardiovascular, renal and metabolism revenue fell 12%, as Farxiga lost exclusivity in the US and volume-based procurement took hold in China.

  1. 1. OncologyGrow its existing oncology medicines significantly.
  2. 2. BioPharmaceuticalsGrow its existing biopharmaceuticals: cardiovascular, renal and metabolism, and respiratory and immunology.
  3. 3. Rare DiseaseGrow its existing rare disease medicines.

Revenue grew from $45.8 billion in 2023 to $58.7 billion in 2025

Total Revenue was $45.8 billion in 2023 when AstraZeneca set the ambition, and $58.7 billion in 2025. For 2026 it guides growth of a mid-to-high single-digit percentage, with Core EPS up a low double-digit percentage; the first half brought $30.7 billion, up 6%.

$0.0billion

Total Revenue in 2025, 73% of the way to $80 billion

A capsule is $1 billion; the outlines are the rest of the ambition.

Oncology makes nearly half of AstraZeneca’s revenue

In the first half of 2026 AstraZeneca’s Total Revenue grew 6% to $30.7 billion. Double-digit growth in oncology and rare disease more than made up for cardiovascular, renal and metabolism, where Farxiga lost exclusivity in the US and volume-based procurement cut prices in China.

Share of first-half 2026 Total Revenue, and growth at constant exchange rates on a year earlier. Infectious disease and other medicines are shown together.

Emissions fell 88% while revenue more than doubled

By the end of 2025 AstraZeneca had cut the emissions from its own operations, scopes 1 and 2, by 88% from 2015. It aims to be carbon zero there in 2026, to halve its supply chain’s scope 3 emissions by 2030, and to reach net zero by 2045 at the latest.

010020020152020202520302026: Carbon zero, scope 1 and 22030: Scope 3 halvedRevenue 100Emissions 100

Both against 2015 = 100: emissions are scope 1 and 2; revenue for 2015 is worked out from 2023’s and the 85% growth AstraZeneca gave for the years between.,

  1. Set the next goal on the day you meet the last.

    AstraZeneca set its $80 billion ambition after reaching the $45 billion goal it had set a decade before. We recommend closing a long goal in public and naming the next one at the same time, so the organisation doesn’t lose its heading.

  2. Say the plan assumes setbacks.

    When a Phase III trial failed in 2026, the CEO said the $80 billion ambition “assumes successes and setbacks”. We recommend building expected failure into a plan’s numbers, and saying so, so that one setback doesn’t read as the plan failing.

  3. Pair growth with what it must not cost.

    AstraZeneca reports its emissions falling as revenue rises, 88% down in its own operations since 2015. We recommend setting a limit alongside a growth goal, and reporting both together.

Sources

  1. 1. AstraZeneca PLC (2024). AstraZeneca to deliver $80bn revenue by 2030. Form 6-K, 21 May 2024. sec.gov
  2. 2. AstraZeneca PLC (2025). Full year and Q4 2024 results. Form 6-K, 6 February 2025. sec.gov
  3. 3. AstraZeneca PLC (2026). Full year and Q4 2025 results. Form 6-K, 10 February 2026. sec.gov
  4. 4. AstraZeneca PLC (2026). AstraZeneca begins trading on NYSE. Form 6-K, 2 February 2026. sec.gov
  5. 5. AstraZeneca PLC (2026). AstraZeneca results: H1 and Q2 2026. Form 6-K, 27 July 2026. sec.gov

Headwater is not connected with AstraZeneca. AstraZeneca, Alexion, Farxiga, and Baxfendy are trade marks of their owners. Updated 29 September 2026.

All company strategies